How PROFHILO is stablished

PROFHILO is developed by using a patented technology resulting in hybrid co-operative complexes between high molecular weight HA and low molecular HA without the use of any enzymatic and mechanical degradation.

Nahyco technology

PROFHILO is not a dermal or bio revitaliser – PROFHILO has opened up a new injectable category – bio remodelling.

Thermal cross- linking changes the character and behaviour of the HA resulting in the formation of the co -operative hybrid complexes with modulate the tissues.  This is also the explanation for the different biological behaviour with respect to H-HA and L-HA alone. One of the main advantages is longevity. hybrid cooperative complexes have proven to be very stable with natural hyaluronidase (BTh) digestion when compared to H-HA widely used in bio-revitalisation products, or L-HA alone resulting in the long- lasting release and the dual actin of the two HA components. This dual action is ideal for remodelling skin laxity.

Advantages

In profhilo L-HA is released slowly from the HA hybrid complexes and therefore does not trigger the first inflammatory cytokines making it very biocompatible. It also increases patient comfort during and after treatment and provides hydration to the skin especially in the epidermis – the hydro effect.

H-HA in profhilo provides a stable HA architecture in the dermis. This gives a volumetric effect – the lift effect.

Another advantage of the stable co – operative hybrid complex when compared to H-HA and L-HA is the increase in the expression levels of type I and type III collagen in fibroblast and type IV and VII collagen in keratinocytes.

This results in improved skin quality and skin hydration both in the dermis and epidermis. There is also increased production of endogenous HA and elastin giving the skin a more youthful look.

 

Highest concentration on the market

Profhilo contains 32mg of low molecular weight HA (80- 100kda) and 32 mg of high molecular weight HA (1100-1400kda) this gives one of the highest concentrations of HA on the market totalling of 64 mg of HA In a 2ml prefilled syringe. Remarkably this can still be extruded using a 29g needle.


Menu